Catalog No.
Product Name
Application
Product Information
Citations
-
Carbonic anhydrase inhibitor
Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase inhibitor of the meta-Disulfamoylbenzene class. -
carbonic anhydrase inhibitor
Dorzolamide HCl is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent and topically applied in the form of eye drops. Dorzolamide HCl is used to lower increased intraocular pressure in open-angle glaucoma and ocular hypertension. -
Carbonic anhydrase inhibitor
Punicalagin is an ellagitannin, a type of phenolic compounds. It is a highly active carbonic anhydrase inhibitor.- Elizabeth Read, .et al. , ANIM FEED SCI TECH, 2019, May, 251(187-197)
-
Carbonic anhydrase inhbitor
Indisulam (E7070) is a carbonic anhydrase inhbitor, is also a novel synthetic sulfon-amide that targets the G1 phase of the cell cycle. -
Carbonic anhydrase inhibitor
Benzenesulfonamide ia an inhibitor of carbonic anhydrases. -
Carbonic Anhydrase Inhibitor
Acetazolamide, a potent carbonic anhydrase (CA) inhibitor, is commonly used in clinical practice as an immediate and readily available option for acute reduction of intraocular pressure(IOP). -
CA9 inhibitor
Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonic anhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells. -
Carbonic anhydrase inhibitor
Ethoxzolamide is a carbonic anhydrase inhibitor with Ki of 1 nM. -
hCA II inhibitor
EMAC10101d is a potent and selective inhibitor of Carbonic Anhydrase Isoform toward hCA II with an inhibitory activity in the low nanomolar range. Ki of 8.1 nM -
Carbonic Anhydrase Inhibitor
Methazolamide is an orally active inhibitor of carbonic anhydrase, demonstrating a Ki of 14 nM for human carbonic anhydrase II. This compound effectively reduces intraocular pressure and exhibits neuroprotective properties, including the ability to inhibit neuronal apoptosis. Methazolamide is applicable in research concerning ophthalmic diseases, such as glaucoma, and cerebrovascular conditions, including subarachnoid hemorrhage. -
Carbonic Anhydrase Inhibitor
Zonisamide is an orally active inhibitor of carbonic anhydrases, demonstrating Ki values of 35.2 nM for human carbonic anhydrase II and 20.6 nM for human carbonic anhydrase V. This compound exhibits neuroprotective properties by promoting anti-apoptotic mechanisms and enhancing manganese superoxide dismutase (MnSOD) expression. Additionally, Zonisamide has been shown to upregulate Hrd1 expression, which contributes to improved cardiac function in animal models of cardiac hypertrophy. Research applications include investigations into seizures, Parkinson's disease, and cardiac hypertrophy. -
Carbonic Anhydrase Probe
(+)-Xylariamide A is a potent probe for carbonic anhydrases, specifically targeting the β-carbonic anhydrases found in mycobacterial and fungal pathogens. It demonstrates significant inhibitory activity, making it a valuable tool for studying the role of carbonic anhydrases in microbial physiology and pathogenicity. Research applications include investigating antifungal and antibacterial mechanisms, as well as exploring therapeutic strategies against resistant strains. -
Carbonic Anhydrase Inhibitor
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid that functions as a potent inhibitor of carbonic anhydrase (CA). It displays inhibition with IC50 values of 2.18 μM for human carbonic anhydrase I (hCA-I) and 17.5 μM for human carbonic anhydrase II (hCA-II). This compound exhibits significant anti-inflammatory properties, making it valuable for research in external ocular inflammation and related therapeutic applications. -
Enpp/Carbonic Anhydrase Inhibitor
Enpp/Carbonic anhydrase-IN-2 is a potent inhibitor of ecto-nucleotide pyrophosphatase/phosphodiesterase (Enpp) and carbonic anhydrases, exhibiting IC50 values of 1.13 µM for NPP1, 1.07 µM for NPP2, 0.74 µM for NPP3, 0.33 µM for CA-IX, and 0.68 µM for CA-XII. This compound demonstrates significant antiproliferative effects on cancer cells while maintaining low cytotoxicity toward normal cell lines. Additionally, Enpp/Carbonic anhydrase-IN-2 has been shown to induce apoptosis, making it a valuable tool for cancer biology research and therapeutic development. -
Enpp/Carbonic Anhydrase Inhibitor
Enpp/Carbonic Anhydrase-IN-1 is a potent inhibitor of ecto-nucleotide triphosphate diphosphohydrolase (ENPP) and carbonic anhydrase, exhibiting IC50 values of 1.36 μM for NPP1, 1.35 μM for NPP2, 3.00 μM for NPP3, 0.88 μM for CA-II, and 1.02 μM for CA-IX. This compound demonstrates significant antiproliferative effects on cancer cells while displaying low cytotoxicity to normal cells. Additionally, Enpp/Carbonic Anhydrase-IN-1 has been shown to induce apoptosis, making it a valuable tool for cancer research and therapeutic investigations. -
Carbonic Anhydrase Inhibitor
Zonisamide sodium is a potent carbonic anhydrase inhibitor, effectively targeting hCA II and hCA V with Kis of 35.2 nM and 20.6 nM, respectively. This compound exhibits neuroprotective properties by promoting anti-apoptotic mechanisms and enhancing the expression of manganese superoxide dismutase (MnSOD). Additionally, Zonisamide sodium has been shown to upregulate Hrd1, contributing to improved cardiac function in animal models of cardiac hypertrophy. Its diverse biological activities make it suitable for investigations related to seizures, Parkinson's disease, and cardiovascular research. -
Carbonic Anhydrase Inhibitor
hCAIX/XII-IN-5 is a selective inhibitor of carbonic anhydrases IX and XII, demonstrating Ki values of 93.9 nM and 85.7 nM, respectively. This compound exhibits notable anti-proliferative effects on cancer cells, leading to cell cycle delay and the induction of apoptosis. hCAIX/XII-IN-5 is a valuable tool for elucidating the roles of carbonic anhydrases in cancer biology and for developing targeted therapeutic strategies. -
Carbonic Anhydrase/Alkaline Phosphatase Inhibitor
ALP/Carbonic Anhydrase-IN-1 is a dual inhibitor of carbonic anhydrase (CA) and alkaline phosphatase (ALP), selectively targeting key isoforms. It demonstrates IC50 values of 0.44 µM for CA-II, 1.61 µM for CA-IX, 0.51 µM for CA-XII, and 0.107 µM for ALP, indicating potent inhibitory activity. This compound is useful in exploring the roles of carbonic anhydrase and alkaline phosphatase in various biological processes and disease models. -
Carbonic Anhydrase Inhibitor
5,6-Dihydro-2H-pyran-2-one is a prodrug that functions as a selective inhibitor of carbonic anhydrases. It exhibits inhibitory activity against the tumor-associated isoform hCA IX and the cytoplasmic form hCA I, with Ki values of 1.35 μM and 8.03 μM, respectively. This compound is valuable for investigating mechanisms of hypoxia-related cancer, providing insights into tumor biology and potential therapeutic targets. -
Carbonic Anhydrase Inhibitor
2-Aminobenzenesulfonamide is an inhibitor of carbonic anhydrase IX, an enzyme implicated in various physiological processes, including respiration and acid-base balance. This compound exhibits significant biological activity, making it a valuable tool in cancer research and the study of metabolic disorders. Its ability to modulate carbonic anhydrase activity positions it as a potential lead compound for therapeutic development in conditions where altered enzyme activity plays a crucial role. -
Carbonic Anhydrase Inhibitor
Lasamide is a potent inhibitor of human carbonic anhydrases, specifically targeting hCAXII and hCAIX with Ki values of 7.54 nM and 2.76 nM, respectively. This compound exhibits significant biological activity in regulating pH and bicarbonate levels, making it valuable in research areas related to cancer, glaucoma, and metabolic disorders. Its specificity for human carbonic anhydrase isoforms allows for precise investigation of the enzyme's role in physiological and pathological processes. -
Carbonic Anhydrase Inhibitor
4-Chloro-3-sulfamoylbenzoic acid is a potent inhibitor of human carbonic anhydrase, specifically targeting cytosolic isoforms hCA I and hCA II, as well as transmembrane isoforms hCA IV and hCA IX. Its inhibition of these enzymes is significant in the study of glaucoma-associated conditions and tumor hypoxia-induced responses. This compound is valuable for research applications focused on exploring the roles of carbonic anhydrases in various physiological and pathological processes. -
COX-2/Carbonic Anhydrase Inhibitor
Polmacoxib is a novel, orally active nonsteroidal anti-inflammatory drug (NSAID) that acts as a dual inhibitor of cyclooxygenase-2 (COX-2) and carbonic anhydrase, with an IC50 value of approximately 0.1 μg/ml for COX-2. It exhibits significant biological activity by inhibiting the growth of colorectal adenomas and tumors in mouse models, making it a promising tool for cancer research. Polmacoxib is valuable for studying the roles of COX-2 and carbonic anhydrase in cancer biology and inflammation. -
Carbonic Anhydrase Inhibitor
hCAI/II-IN-6 is a selective inhibitor of human carbonic anhydrase isoforms II and VII, exhibiting Ki values of 4.9 nM and 6.5 nM, respectively. This compound demonstrates pronounced anticonvulsant activity and provides protective effects against maximal electroshock (MES) seizures in vivo. hCAI/II-IN-6 serves as a valuable tool for research studies focusing on epilepsy and related neurophysiological conditions. -
Carbonic Anhydrase II Inhibitor
Carbonic Anhydrase Inhibitor 2 specifically targets carbonic anhydrase II, functioning as an effective inhibitor. This compound is primarily used in research applications related to the modulation of intraocular pressure and may offer insights into potential therapeutic strategies for glaucoma. Its ability to influence carbonic anhydrase activity highlights its significance in biochemical studies and pharmacological investigations. -
Carbonic Anhydrase Inhibitor
hCAIX-IN-18 is a potent inhibitor of carbonic anhydrase (CA), demonstrating inhibition constants (Kis) of 3.5 nM, 9.4 nM, 43.0 nM, and 8.2 nM for human carbonic anhydrases I, II, IX, and XII, respectively. This compound is particularly relevant for cancer research, where it may affect tumor growth and metabolism through the modulation of CA activity. Its specificity and efficacy make it a valuable tool for investigating the role of carbonic anhydrases in various pathological conditions. -
Carbonic Anhydrase II Inhibitor
Dorzolamide is a potent inhibitor of carbonic anhydrase II, exhibiting an IC50 of 0.18 nM for red blood cell CA-II and 600 nM for CA-I. This compound is known for its therapeutic applications in reducing intraocular pressure and has demonstrated potential anti-tumor activity. It is a valuable reagent for research in cancer biology and ocular studies. -
Carbonic Anhydrase Inhibitor
Carbonic anhydrase inhibitor 17 is a pyridazine-tethered sulfonamide that specifically targets carbonic anhydrase II with an impressive IC50 value of 0.63 nM. This compound demonstrates potent inhibitory activity, making it a valuable tool for studying the role of carbonic anhydrases in various physiological and pathological processes. Its application is significant in research areas such as enzyme regulation, metabolic disorders, and cancer biology. -
Carbonic Anhydrase Inhibitor
AHR-15010 is a potent carbonic anhydrase inhibitor with an IC50 value of 0.13 μM. This compound exhibits anti-arthritic activity, making it a valuable tool for research on arthritis and related inflammatory conditions. Its ability to inhibit carbonic anhydrase opens avenues for studying therapeutic strategies in managing arthritis. -
Carbonic Anhydrase Inhibitor
hCAIX-IN-11 is a selective inhibitor of carbonic anhydrase IX (hCA IX) and XII (hCA XII), demonstrating Ki values of 32.7 nM and 623.5 nM, respectively. hCA IX and hCA XII are transmembrane isoforms that serve as biomarkers for various tumors, making them critical targets for cancer research. In addition to its role in tumor biology, hCA XII is involved in regulating acid-base homeostasis in both normal and cancerous cells, supporting its relevance in studies of metabolic regulation and tumor microenvironments. -
Carbonic Anhydrase Inhibitor
L-693612 is a potent, orally active carbonic anhydrase inhibitor. It effectively modulates bicarbonate and pH levels, making it a valuable tool for research into metabolic and respiratory disorders. This compound supports investigations into the therapeutic potential of carbonic anhydrase inhibition in various biological contexts. -
Carbonic Anhydrase Inhibitor
hCAII-IN-9 is a potent inhibitor of carbonic anhydrases, specifically exhibiting IC50 values of 1.18 μM for hCA II, 0.17 μM for hCA IX, and 2.99 μM for hCA XII. This compound demonstrates significant potential for research applications related to the modulation of carbonic anhydrase activity in various physiological and pathological conditions. Notably, hCAII-IN-9 does not exhibit permeability across the blood-brain barrier, making it suitable for studies focused on peripheral rather than central effects. -
Carbonic Anhydrase II Inhibitor
Carbonic Anhydrase Inhibitor 3 is a potent inhibitor of Carbonic Anhydrase II. This compound effectively reduces intraocular pressure, making it a valuable tool in the study of glaucoma and related ocular conditions. Its role in modulating intraocular pressure offers insights into therapeutic strategies for managing glaucoma. -
Carbonic Anhydrase II Inhibitor
Brinzolamide hydrochloride is a selective inhibitor of carbonic anhydrase II with an IC50 of 3.2 nM. It effectively lowers intraocular pressure (IOP) by targeting ciliary carbonic anhydrase II, leading to a reduction in aqueous humor secretion. This compound is particularly valuable for research applications related to glaucoma and other ocular conditions. -
Carbonic anhydrase Inhibitor
Dichlorphenamide disodium is a specific inhibitor of carbonic anhydrase, which functions by reducing the secretion of aqueous humor in the eye. This compound is effective in lowering intraocular pressure and is primarily utilized in glaucoma research. Its role in studying carbonic anhydrase inhibition provides insights into therapeutic strategies for managing elevated intraocular pressure and related ocular conditions. -
Carbonic Anhydrase Inhibitors
L-650719 is a potent carbonic anhydrase inhibitor, exhibiting a Ki value of 10 nM for carbonic anhydrase II (CA II). This compound has demonstrated significant efficacy in reducing intraocular pressure in rabbit models, highlighting its potential for therapeutic application. L-650719 is suitable for research focused on glaucoma and related ocular conditions. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 11 is a selective inhibitor targeting carbonic anhydrases, particularly exhibiting Ki values of 40 nM for CA II, 39 nM for CA IX, and 200 nM for CA XII. This compound demonstrates potential biological activity in modulating pH regulation and ion transport. It is valuable for research applications related to cancer, glaucoma, and other conditions where carbonic anhydrase plays a critical role in pathology. -
Carbonic Anhydrase Inhibitor
Carbonic anhydrase inhibitor 10 is a highly selective inhibitor of human carbonic anhydrase IX (hCA IX), with a Ki value of 6.2 nM. This compound demonstrates significant anti-proliferative activity in the MCF-7 cancer cell line, exhibiting an IC50 of 11.9 μM. Carbonic anhydrase inhibitor 10 is suitable for applications in cancer research, particularly in studies investigating the role of hCA IX in tumorigenesis and malignancy. -
Carbonic Anhydrase Inhibitor
Carbonic Anhydrase Inhibitor 13 is a potent inhibitor of carbonic anhydrase (CA), characterized by its 3-methylthiazolo[3,2-a]benzimidazole moiety linked to a zinc-coordinating benzenesulfonamide via a ureido linkage. This compound demonstrates significant inhibition of carbonic anhydrase activity, making it a valuable tool for investigating the role of CA in various physiological processes. Its applications extend to studies in cancer, glaucoma, and metabolic disorders, where modulation of CA activity may provide therapeutic insights. -
Carbonic Anhydrases Inhibitor
Antibacterial agent 167 is a potent inhibitor of pathogenic bacterial carbonic anhydrases. It demonstrates significant antibacterial activity against Neisseria gonorrhoeae strains, effectively inhibiting growth at concentrations between 16 and 64 µg/mL. This compound serves as a valuable tool for research into antibacterial mechanisms and the development of new therapeutic strategies against resistant bacterial infections. -
Carbonic Anhydrase Inhibitor
L-693612 hydrochloride is a potent inhibitor of carbonic anhydrase, demonstrating both oral and topical bioactivity. Its primary mechanism involves the inhibition of carbonic anhydrase enzymes, which play a critical role in regulating acid-base balance and fluid secretion. This compound is widely used in research applications targeting therapeutic areas such as glaucoma and edema, facilitating studies on the modulation of intraocular pressure and fluid management. -
Carbonic Anhydrase Inhibitor
HCAIX-IN-2 is a selective inhibitor of carbonic anhydrase, specifically targeting isoforms hCA IX and hCA XII with Ki values of 24.6 nM and 45.3 nM, respectively. This compound exhibits significant biological activity in modulating carbonic anhydrase activity, making it a valuable tool in cancer research and therapeutic development. Its inhibitory effects may provide insights into the role of carbonic anhydrases in tumor progression and offer potential avenues for treatment strategies. -
Carbonic Anhydrase Inhibitor
O-Desmethyl Brinzolamide hydrochloride is a potent carbonic anhydrase inhibitor, demonstrating a Kd of 0.136 nM for carbonic anhydrase II and an IC50 of 165 nM for carbonic anhydrase IV. This active metabolite of Brinzolamide is essential for research focused on the regulation of bicarbonate ions and pH homeostasis in various biological systems. It holds potential applications in studying conditions driven by abnormal carbonic anhydrase activity, including glaucoma and other metabolic disorders. -
Carbonic Anhydrase Inhibitor
Disulfamide is a potent carbonic anhydrase inhibitor with an IC50 value of 0.07 μM. By inhibiting carbonic anhydrase, Disulfamide disrupts the reabsorption of sodium and bicarbonate in the proximal tubule, leading to increased diuresis. This compound is valuable for research applications focusing on renal physiology and electrolyte balance.
